The problem of viral resistance in chronic hepatitis B therapy
Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2009, Vol 26, Issue 3
Abstract
Available agents for the treatment of chronic HBV infection include interferon-alpha, the nucleoside analogues lamivudine, telbivudine, entecavir and the noucleotide analogue adefovir and tenofovir. When nucleoside-nucleotide analogues are used, patients require a long duration of treatment, especially in HBeAg negative disease, with the potential for developing antiviral resistance, which limits their long-term effectiveness. Interferon-alpha lacks viral resistance selection. Resistance rates vary by compound. Lamivudine is associated with the development of viral resistance in up to 70% within 5 years, adefovir dipivoxil in 29% after 5 years, entecavir in <1% in naive patients for up to 4 years (39% in 4 years in lamivudine-resistant patients) and telbivudine in 22% after 2 years of therapy. Clinical consequences of nucleoside-noucleotide resistance include loss of viral response (i.e., a rise in serum HBV DNA), biochemical dysfunction with an increase in aminotransferases, and overt hepatic failure (in patients with more advanced underlying liver disease). The initial choice of antiviral agent should take into consideration both the potency and the incidence of resistance, with serial HBV DNA determination to confirm adequate viral suppression. A suboptimal response to therapy with continued high-level replication identifies a patient at high risk for viral resistance, and is an indication for a change in antiviral strategy. Routine on-treatment monitoring of HBV DNA levels is imperative for detecting virologic breakthrough as early as possible, and for transitioning patients to rescue therapy before biochemical failure and loss of response occurs. For lamivudine resistant HBV infection, adefovir or tenofovir, and for adefovir resistance lamivudine should be added. In conclusion, monitoring for drug resistance during therapy and its prompt management are crucial in managing the antiviral treatment of HBV patients.
Authors and Affiliations
S. DOURAKIS
Keywords
Related Articles
- EP ID EP160128
- DOI -
- Views 62
- Downloads 0
Solitary rectal ulcer syndrome
No abstract available
Oral candidiasis in patients with hematological malignancies
OBJECTIVE Study of the clinical forms of oropharyngeal candidiasis in patients with hematological malignancies during their hospitalization. METHOD Eighty-eight patients aged between 18–88 years were included in the s...
Tyrosine kinase inhibitor –<br /> a new targeted therapy for chronic myeloid leukemia
The treatment of patients with Ph(+) or BCR-ABL(+) chronic myeloid leukemia (CML) did not improve very greatly in the 1990s. It is now widely accepted that patients treated by allogeneic stem cell transplantation may be...
What are the pitfalls in laboratory analysis for thyroid test on filter paper collected samples?
No abstract available
Colonialism and smallpox in the Ionian Islands during the "British protection": The case of vaccination in Corfu (1852)
This paper presents the British colonial health policy concerning the case of vaccination against smallpox in the Ionian Islands (1815−1864). The study was based on the registers of the Executive Police Archives during t...